Top NYC, NY Health Tech Companies With Best Stability & Growth (1,079)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Profitability: Company materials describe sustained annual profitability since 2023 and cash-flow positivity, pairing growth with disciplined financial health. It also reports meeting efficiency benchmarks, noting it exceeded the Rule of 40 in 2025.

Strong Revenue Growth: Disclosures point to multi-year revenue expansion with momentum described as accelerating, indicating robust top-line performance. This growth is presented alongside expanding provider and patient scale.

Strategic Partnerships: The platform is increasingly embedded across external channels through integrations with Healthgrades, Yelp, Google Gemini, and payer portals, broadening distribution and demand capture. These arrangements signal deeper ecosystem reach beyond the core marketplace.

Market Expansion: National and payer footprint have broadened materially, with availability across all 50 states, plan relationships rising toward 100+, and sharp increases in providers, patients, and appointments. This widening reach indicates an ability to capture demand across geographies and insurance lines.

Investor Backing & Capital Strength: A $100M Series D at a roughly $2.3B valuation alongside substantial prior financing reflects strong access to growth capital. This position supports continued scaling of the network, product investments, and deeper insurer integrations.

Strong Revenue Growth: Revenue is described as having increased significantly over a recent 12‑month period, with earlier disclosures citing outsized year‑over‑year gains. Coupled with rising session volumes, this points to robust top‑line momentum despite limited public financial detail.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Market Expansion: Patient reach rose from 22M in 2022 to 25M in 2023 and 50M by January 2025, alongside new wins such as Sanford Health and multiple physician groups adopting the platform. Kora was also adopted by 10 provider organizations within its first year, reinforcing broader commercial uptake.

Product Line Growth: Cedar expanded from payments/billing into affordability, AI support, and the Kora AI agent in 2025–26, later broadening into the multi‑agent Kora Platform. Additional launches like Cedar Cover extended capabilities into Medicaid enrollment, renewals, and denials resolution.

Innovation-Driven Growth: AI‑driven workflows are central, with Kora handling roughly 400,000 patient calls in its first year and continued rollout of Cedar Intelligence in 2026. Recognition and ongoing AI feature releases signal a strategy centered on technology-led growth in healthcare financial workflows.

Strong Revenue Growth: Estimates indicate annualized revenue rose sharply in 2024, with acceleration tied to GLP-1/obesity care. Evidence cites roughly $598M annualized revenue in 2024 versus about $360M in 2023.

Market Expansion: Recent launches and channel moves broadened reach, including nationwide availability of the Wegovy pill and a surge of new customers in early 2026. The platform reports helping millions of patients across nearly every U.S. county.

Strategic Partnerships: Direct integrations with major manufacturers (e.g., Novo Nordisk’s NovoCare for Wegovy and additional GLP-1 collaborations) position the company as a distribution/access channel. Novo Nordisk specifically described the company as part of its direct-to-patient expansion.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.

Strong Revenue Growth: ARR is reported to have surpassed $200M by June 2026 after crossing $100M in early 2025, with five consecutive years of 100% year-over-year growth. This consistent doubling signals rapid scaling at substantial revenue levels.

Investor Backing & Capital Strength: Funding rounds include $75M in 2024 at a valuation above $1B and a $250M Series E in 2025 at a reported $2.2B, with total capital raised cited at $400M+. Such late-stage financing and rising valuations indicate robust access to growth capital.

Strong Market Position & Advantage: Adoption is described as reaching roughly 1 in 6 U.S. apartments, with deep penetration among large property managers and hundreds of operators. Expansion into healthcare and notable distribution relationships have broadened its commercial footprint.

Investor Backing & Capital Strength: Funding momentum is pronounced, with a $35M Series A (Mar 2025), $100M Series B (Sep 2025), and a $70M Series C (Sep 2026) bringing total capital to about $225M at a valuation above $500M. This pattern signals sustained investor appetite and a materially stronger capital position.

Strong Revenue Growth: Reporting indicates subscription revenue nearly quadrupled year over year to about $29M, while contracted revenue surpassed $60M. These figures point to rapid scaling of recurring and booked revenue.

Market Expansion: Commercial reach appears to be growing, with monitoring of roughly 40,000 residents across just over 500 senior-living communities and new deployments among named operators. Expanding partnerships and portfolio rollouts suggest a widening customer footprint.

Market Expansion: Adoption appears to have increased from 19,000+ hospitals in June 2023 to 23,000+ currently, indicating continued penetration of the U.S. veterinary market. The platform is also described as powering purchasing infrastructure for the majority of several practice types nationwide.

Product Line Growth: The offering has expanded from a price-comparison tool into a broader procurement ecosystem spanning distributors, manufacturers, and diagnostic labs, with a catalog covering 99.9% of products veterinarians use. This evolution points to a shift toward comprehensive procurement infrastructure rather than a single-point solution.

Strong Market Position & Advantage: A 23,000+ hospital installed base and a supplier-side marketplace marketed as access to 23,000+ clinics suggest reinforcing network effects. Monetization on the supplier/manufacturer side and corporate capabilities further underscore centrality in the purchasing workflow.

Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.

Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.

Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.

Market Expansion: Geographic reach is described as nationwide through Medicare, with pages indicating coverage in 48 to all 50 states, signaling active expansion. State-by-state therapist listings and nationwide positioning reinforce a broad and growing footprint.

Product Line Growth: Service scope expanded from therapy for older adults to a broader platform that includes behavioral health, advocacy, wellness classes, mind exercises, and AI care agents. This indicates growth beyond the original core offering.

Strong Hiring & Retention: Headcount and hiring activity are depicted as rising quickly, with quarter-over-quarter increases reported by company intelligence trackers and ongoing recruiting across clinical and corporate roles. This workforce build-out supports scaling operations.

Strong Revenue Growth: Top-line revenue is reported to have grown strongly on a multi-year basis through 2023, with additional indications of continued increases into 2025–2026. This provides the clearest quantitative signal of momentum for a private company with limited disclosures.

Market Expansion: The provider network and product footprint have broadened, including new launches such as programmatic access and a consumer health media offering alongside partnerships that extend reach. These moves show growth beyond core point-of-care screens into adjacent adtech and consumer channels.

Investor Backing & Capital Strength: Advent International’s 2025 agreement to acquire the company and continued investment signal substantial sponsor support for scaling. Such backing typically underwrites further network growth and product innovation.

Market Expansion: Reported enrollments of roughly 250,000 in 2025 and a broker base exceeding 10,000 point to a rapidly widening operating footprint. AEP 2025 production metrics and tens of thousands of contracts processed further suggest the platform is scaling beyond its 2024 funding milestone.

Investor Backing & Capital Strength: A $25M Series B in January 2024, reportedly at a significant valuation step-up, underscores access to growth capital. Independent listings also record total funding in the high-$30Ms range, reinforcing external validation of capitalization.

Strong Hiring & Retention: Headcount reportedly expanded from around 40 to roughly 130 by 2025, and current postings include senior roles across revenue operations, engineering, product, and agent/customer experience. Active requisitions signal continued investment in growth infrastructure.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Investor Backing & Capital Strength: Evidence indicates a $55M Series B in 2026 brought cumulative funding above $73M to accelerate hiring, R&D, and platform adoption. This capital position supports scaling operations and product development.

Strong Revenue Growth: Company materials state revenue increased 4× in the 12 months prior to April 2024, with earlier periods citing 24× growth and expectations to more than double in 2022. These signals indicate rapid top-line expansion, though current figures are not independently audited.

Product Line Growth: The offering has expanded beyond payment integrity into utilization management and appeals while launching AI agents for DRG validation, readmissions, and emergency-department reviews. This broadening scope increases relevance across health‑plan claims workflows.

Investor Backing & Capital Strength: Multiple large financings (e.g., a $65M Series C led by Goldman Sachs Alternatives) alongside additional facilities (such as a $35M Stifel debt facility and a $50M growth-capital commitment) indicate strong access to capital and confidence to scale. These transactions are explicitly framed as funding nationwide platform expansion and operational build-out.

Market Expansion: Deployments are described as spanning hundreds of communities across 26 states, with portfolio-wide rollouts such as Navion’s phased deployment across 47 communities and continued clinic/location openings in targeted markets. Expansion plans emphasize entering new geographies and broadening presence across the senior-care continuum.

Product Line Growth: The offering has broadened from a single workflow product into an integrated platform that includes AI-powered monitoring/fall management (Sage Detect), EHR-integrated tasking and labor tools, and skilled-nursing solutions. Expanded integrations with EHR systems (e.g., Yardi, ALIS, ECP, PointClickCare, August Health) further extend product scope and use cases.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.